Resources

Lesson 1: Biotechnology as the manipulation of life: the recombinant DNA debate of the 1970s

RETURN TO CLASS RESOURCE OVERVIEW

Choose Another Lesson

close

Lessons

  1. Lesson 1: Biotechnology as the manipulation of life: the recombinant DNA debate of the 1970s

    Read More

  2. Lesson 2: Biotechnology as big business: patenting life from Chakrabarty to Myriad

    Read More

  3. Lesson 3: Biotechnology as a new eugenics: genetic testing and reproductive technologies

    Read More

  4. About the Author

    Read More

Introduction

The era of biotechnology unfolded amid intense public scrutiny of science and technology. By the early 1970s, issues like nuclear disarmament, overpopulation and environmental crisis, and the revelation of the mistreatment of human subjects of scientific and medical research (most notoriously in the Tuskegee Syphilis Study), had drawn sharp and sustained public criticism and calls for government intervention. Biotechnology developed amid this context of public pessimism about science and technology. As a result, although in its earliest years the experts managed to confine discussions of biotechnology to professional forums, by the mid to late 1970s, the debates had exploded into public view and occasioned broad public involvement. Whether the lay public had any right to a voice in scientific and technical matters was itself a central point of contention.

Read More

Discussion Reading

Krimsky, Sheldon. Biotechnics and Society: The Rise of Industrial Genetics. Westport, CT: Praeger, 1991, chapters 1, 2, 5, 6, 7, 8.

Wald, George. “The Case Against Genetic Engineering.” The Sciences 16, no. 5 (1976): 6–11.

National Library of Medicine. “The Paul Berg Papers.” Profiles in Science. https://profiles.nlm.nih.gov/spotlight/cd.

The following digitized primary sources from the digital archive:

Debate Resources

  • Durant, John. “‘Refrain from Using the Alphabet’: How Community Outreach Catalyzed the Life Sciences at MIT.” In Becoming MIT: Moments of Decision. Edited by David Kaiser. Cambridge, MA: MIT Press, 2010, pp. 145–163.
  • Gottweis, Herbert. “Molecularizing Risk: The Asilomar Legacy in the United States and Europe.” In Governing Molecules: the Discursive Politics of Genetic Engineering in Europe and the United States. Cambridge, MA: MIT, 1998. pp. 77–152.
  • Weiner, Charles. “Recombinant DNA Policy: Asilomar Conference.” In Encyclopedia of Ethical, Legal, and Policy Issues in Biotechnology. Edited by Thomas J. Murray and Maxwell J. Mehlman. New York, NY: Wiley, 2010, Vol. 2, p. 210.
  • “Historical note: The Recombinant DNA Controversy.” Massachusetts Institute of Technology, Oral History Program. Massachusetts Institute of Technology, Department of Distinctive Collections, Cambridge, Massachusetts https://archivesspace.mit.edu/repositories/2/resources/658.
  • “Research Controversy in Cambridge, Ma.” Newsletter on Science, Technology, & Human Values, no. 17 (1976): 4–6. http://www.jstor.org/stable/751682.

Discussion questions:

  1. What were the main events of the early decades of recombinant DNA research and policy?
  2. What were Wald’s claims about the dangers of DNA experimentation, and how did his opponents counter them? Did you find either side convincing; why or why not?
  3. How and why did the different sides define the risks of rDNA research differently? What sorts of evidence did each side use?
  4. How did the ideas about risk change over time, as the debate moved to different forums, from the Asilomar meeting and the Recombinant Advisory Committee to the public debates over deliberate release in the 1980s?

Debate questions:

  1. Is the process of rDNA “instant evolution,” a process qualitatively different from conventional breeding and natural evolution?
  2. Should the experts be writing the rules for themselves, or is this a conflict of interest?
  3. Do living things have “inherent natures” that should not be tampered with—and where do we draw the line?